A notable difference between the SLAM-blind MeV system and current nectin4-retargeted herpesvirus appears to be that the MeV recombinant infected all hN4-positive cancer cells regardless of their extent of nectin4 expression; a modest infection was reported also with some cells whose nectin4 expression was negative or below the detection limit. This evidence concerns the gene NECTIN4 and cancer.